Skip to Content

Circulating Tumor DNA – A Biomarker for Adjuvant Chemotherapy?

Listen to Van Morris, directly from ASCO GI, discuss the NRG-GI005 (COBRA) trial, a phase II study examining the use of circulating tumor DNA as a biomarker for adjuvant chemotherapy benefit in stage IIa colon cancer.

Van Morris

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top